Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

EHTH vs CDLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EHTH Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–4 Matrix Metrics)

EHTH Overall Winner 6-Pillar Tally: EHTH 4 – 2 CDLX Matrix Metrics: EHTH 5 – 4 CDLX

As of Nov 17, 2026, eHealth, Inc. (EHTH) is the stronger overall head-to-head candidate over Cardlytics, Inc. (CDLX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EHTH carries a Unified Composite Score of 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin), whereas CDLX carries 41.6/100 (SELL) at $1.29 (36.5x Forward P/E, -19.3% operating margin).

  • Composite vs. Pillar Nuance: While CDLX currently prints a higher short-term Unified Composite Score (41.6/100 SELL vs. EHTH 40.8/100 SELL), EHTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (11.9% vs. -19.3% operating margin) and revenue trajectory (-60.5% vs. -30.0% YoY).
  • Defensive Composite Rating Caution: Although EHTH compares more favorably head-to-head, both EHTH (40.8/100 SELL) and CDLX (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: EHTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9); meanwhile CDLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EHTH vs CDLX
EHTH NASDAQ Head-to-Head Winner
eHealth, Inc.
Insurance Agents, Brokers & Service
$0.35
-9.36% 1D
Market Cap $13.4M
TTM Revenue $469M
Forward P/E 0.2x
Beta / 30D Vol 1.61β · 117% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 25
RSI-14: 24.9 · SMA20: $0.50 · SMA50: $0.65
CDLX NASDAQ
Cardlytics, Inc. Common Stock
Services-Computer Programming, Data Processing, Etc.
$1.29
+0.0% 1D
Market Cap $8.2M
TTM Revenue $176M
Forward P/E 36.5x
Beta / 30D Vol 1.82β · 109% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 25.0 Fund 46.0 Flow 60.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.0%), weak momentum, RSI 26
RSI-14: 25.8 · SMA20: $1.73 · SMA50: $2.49

6-Pillar Scorecard Institutional Category Breakdown (EHTH 4 – 2 CDLX)

Columns: Metric · EHTH · CDLX
1. Valuation Multiples EHTH
Forward P/E 0.2x 36.5x
Trailing P/E 0.2x 36.5x
PEG Ratio 0.72x N/M
EV / Revenue N/M N/M
2. Growth & Scale EHTH
Revenue Growth (YoY) -60.5% -30.0%
Earnings Growth (YoY) -17.6% -56.7%
TTM Revenue (USD) $469M $176M
Market Cap $13.4M $8.2M
3. Profitability & Quality EHTH
Gross Margin 100.0% 49.7%
Operating Margin 11.9% -19.3%
Net Profit Margin 4.9% -20.8%
Return on Equity (ROE) 2.6% -513.2%
4. Balance Sheet & Cash Flow EHTH
Cash Generation (TTM) $58M EBITDA -$16M
Cash Flow Margin 12.4% EBITDA Mgn -9.2%
Net Cash / Leverage $15.36 Book/Sh · 2.6% ROE -513.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CDLX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 128.7% (56th %ile) 0.8% (<1st %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CDLX
OpEx & R&D Intensity N/A 69.0% of Rev ($121M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance Brokers Operator Advertising Agencies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EHTH (5) vs CDLX (4)
Institutional Metric EHTH CDLX Criterion Row Edge
Market Capitalization
Scale
$13.4M $8.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
0.2x 36.5x Lower Multiple EHTH
Forward P/E Ratio
Valuation
0.2x 36.5x Lower Multiple EHTH
Revenue Growth (YoY)
Growth
-60.5% -30.0% Higher Growth CDLX
Operating Margin (TTM)
Profitability
11.9% -19.3% Higher Margin EHTH
Net Profit Margin
Profitability
4.9% -20.8% Higher Margin EHTH
Return on Equity (ROE)
Capital Efficiency
2.6% -513.2% Higher ROE EHTH
52-Week Range Position
Momentum
0% ($0–$5) 13% ($1–$6) Stronger Trend CDLX
Beta / 30D Volatility
Risk Regime
1.61β · 117% Vol 1.82β · 109% Vol Lower Realized Risk CDLX
Unified Institutional Score
Composite Signal
40.8 / 100 (SELL) 41.6 / 100 (SELL) Higher Composite CDLX
Trailing 12M Revenue (USD)
Operating Scale
$469M $176M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 49.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.72x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$58M EBITDA ($15.36 Book/Sh · 2.6% ROE) -$16M (-513.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDLX +8.74 pp
EHTH: -38.63% · CDLX: -29.89%
3M Horizon CDLX +2.31 pp
EHTH: -72.03% · CDLX: -69.72%
6M Horizon CDLX +196.74 pp
EHTH: -80.3% · CDLX: +116.44%
1Y Horizon CDLX +83.73 pp
EHTH: -90.92% · CDLX: -7.19%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EHTH vs CDLX. Trailing 12-month operating profitability (EHTH 11.9% vs CDLX -19.3%) and valuation multiples (EHTH 0.2x vs CDLX 36.5x Forward P/E) are benchmarked directly in Pillar 4 below.

EHTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$469M
Gross Margin100.0%
Op. Margin11.9%
ROE / Fwd P/E2.6% · 0.2x
CDLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$176M
Gross Margin49.7%
Op. Margin-19.3%
ROE / Fwd P/E-513.2% · 36.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EHTH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 128.7%
IV Percentile 56th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EHTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDLX BREAKDOWN
109d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EHTH Moat Profile Cyclical / Execution-Driven Positioning
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $13.4M market capitalization and 11.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDLX Moat Profile Cyclical / Execution-Driven Positioning
Advertising Agencies Operator
Competes within the Advertising Agencies value chain with $8.2M market capitalization and -19.3% operating margin.
OpEx & R&D Reinvestment 69.0% of Rev ($121M)
90D Engineering Disclosures 0 Published

Investor FAQ EHTH vs CDLX Key Questions & Quantitative Answers

As of Nov 17, 2026, eHealth, Inc. (EHTH) is the stronger overall head-to-head candidate over Cardlytics, Inc. (CDLX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EHTH carries a Unified Composite Score of 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin), whereas CDLX carries 41.6/100 (SELL) at $1.29 (36.5x Forward P/E, -19.3% operating margin). Composite vs. Pillar Nuance: While CDLX currently prints a higher short-term Unified Composite Score (41.6/100 SELL vs. EHTH 40.8/100 SELL), EHTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (11.9% vs. -19.3% operating margin) and revenue trajectory (-60.5% vs. -30.0% YoY). Defensive Composite Rating Caution: Although EHTH compares more favorably head-to-head, both EHTH (40.8/100 SELL) and CDLX (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: EHTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9); meanwhile CDLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EHTH leads the Growth & Scale pillar: EHTH posts -60.5% YoY revenue growth and -17.6% YoY earnings growth on $469M TTM revenue (100.0% gross margin, 11.9% operating margin), compared with CDLX at -30.0% YoY revenue growth and -56.7% YoY earnings growth on $176M TTM revenue (49.7% gross margin, -19.3% operating margin). On trailing 12-month operating scale, EHTH generates $469M in USD-normalized revenue versus $176M for CDLX. In operating R&D and SG&A reinvestment, EHTH deploys N/A (0 90-day corporate R&D disclosures) versus 69.0% of Rev ($121M) (0 disclosures) for CDLX.

EHTH screens cheaper on headline valuation multiples. EHTH trades at 0.2x Forward P/E, 0.2x Trailing P/E, 0.72x PEG, and N/M EV/Revenue (12.4% EBITDA margin), whereas CDLX trades at 36.5x Forward P/E, 36.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (-9.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EHTH (2.6% ROE) versus CDLX (-513.2% ROE) capital efficiency.

In options market volatility and institutional positioning, EHTH carries 128.7% implied volatility (56th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 117% Vol realized risk). By comparison, CDLX carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.